Symrise Valuation

Is 1SYM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1SYM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1SYM (€102.8) is trading below our estimate of fair value (€128.46)

Significantly Below Fair Value: 1SYM is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1SYM?

Key metric: As 1SYM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1SYM. This is calculated by dividing 1SYM's market cap by their current earnings.
What is 1SYM's PE Ratio?
PE Ratio36.5x
Earnings€392.39m
Market Cap€14.31b

Price to Earnings Ratio vs Peers

How does 1SYM's PE Ratio compare to its peers?

The above table shows the PE ratio for 1SYM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average13.7x
SOL SOL
23.6x10.0%€3.3b
BZU Buzzi
6.8x1.7%€6.5b
MGS Magis
7.3xn/a€60.9m
CULT CULTI Milano
17.1x19.0%€40.2m
1SYM Symrise
36.5x13.7%€14.3b

Price-To-Earnings vs Peers: 1SYM is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the peer average (13.7x).


Price to Earnings Ratio vs Industry

How does 1SYM's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
1SYM 36.5xIndustry Avg. 17.2xNo. of Companies11PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1SYM is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the European Chemicals industry average (17.5x).


Price to Earnings Ratio vs Fair Ratio

What is 1SYM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1SYM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36.5x
Fair PE Ratio21.2x

Price-To-Earnings vs Fair Ratio: 1SYM is expensive based on its Price-To-Earnings Ratio (36.5x) compared to the estimated Fair Price-To-Earnings Ratio (21.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1SYM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€102.80
€119.33
+16.1%
8.1%€137.00€105.00n/a18
Dec ’25€104.65
€119.83
+14.5%
8.5%€138.00€105.00n/a18
Nov ’25€112.45
€122.32
+8.8%
10.1%€138.00€92.50n/a20
Oct ’25€124.75
€121.17
-2.9%
10.8%€139.00€90.00n/a20
Sep ’25€118.40
€118.87
+0.4%
10.2%€135.00€90.00n/a20
Aug ’25€112.45
€117.82
+4.8%
10.5%€134.00€90.00n/a20
Jul ’25n/a
€116.77
0%
10.4%€134.00€90.00n/a20
Jun ’25n/a
€113.67
0%
9.6%€130.00€90.00n/a20
May ’25n/a
€113.52
0%
9.9%€130.00€90.00n/a20
Apr ’25n/a
€110.44
0%
9.1%€126.00€90.00n/a20
Mar ’25n/a
€107.49
0%
9.2%€126.00€83.00n/a20
Feb ’25n/a
€108.17
0%
9.2%€126.00€83.00n/a20
Jan ’25n/a
€107.44
0%
8.8%€126.00€83.00€103.9519
Dec ’24n/a
€107.55
0%
9.0%€126.00€83.00€104.6519
Nov ’24n/a
€106.23
0%
8.4%€126.00€83.00€112.4519
Oct ’24n/a
€108.23
0%
9.2%€126.00€83.00€124.7519
Sep ’24n/a
€108.47
0%
9.0%€126.00€83.00€118.4020
Aug ’24n/a
€110.02
0%
9.9%€126.00€86.00€112.4520
Jul ’24n/a
€110.09
0%
9.6%€126.00€86.00n/a21
Jun ’24n/a
€112.61
0%
10.0%€132.60€86.00n/a22
May ’24n/a
€112.20
0%
10.2%€132.60€86.00n/a22
Apr ’24n/a
€110.77
0%
10.6%€132.60€86.00n/a21
Mar ’24n/a
€113.10
0%
9.8%€132.60€90.00n/a21
Feb ’24n/a
€113.10
0%
9.8%€132.60€90.00n/a21
Jan ’24n/a
€116.15
0%
10.0%€140.00€91.00n/a21

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 08:28
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Symrise AG is covered by 62 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Konstantin WiechertBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research